Alergia e Imunologia

Atualização | Terapias para disfunções olfatórias.

7 Fev, 2022 | 13:32h

Therapies for Olfactory Dysfunction — an Update – Current Allergy and Asthma Reports (se o acesso a este link for pago, tente este)

O que a onda da variante Ômicron está revelando sobre a imunidade humana.

4 Fev, 2022 | 17:34h

What the Omicron wave is revealing about human immunity – Nature

Anafilaxia: destaques da nova diretriz.

4 Fev, 2022 | 17:18h

Anaphylaxis: Highlights from the practice parameter update – Cleveland Clinic Journal of Medicine

Artigo original: Anaphylaxis—a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis – Journal of Allergy and Clinical Immunology

Revisão | Eosinofilia e disfunção eosinofílica autoimune na saúde e na doença.

4 Fev, 2022 | 15:35h

Eosinophils and eosinophilic immune dysfunction in health and disease – European Respiratory Review

Breve revisão | Reações de hipersensibilidade a vacinas em crianças: do sarampo ao SARS-CoV-2.

4 Fev, 2022 | 15:34h

Hypersensitivity reactions to vaccines in children: from measles to SARS-CoV-2 – Pediatric Allergy and Immunology

Comentário: Vaccine hypersensitivity in children – News Medical

FDA interrompe o uso de anticorpos monoclonais que não funcionam contra a Ômicron.

31 Jan, 2022 | 08:56h

FDA halts use of antibody drugs that don’t work vs. omicron – Associated Press

Conteúdo relacionado: Lab study shows new antiviral pills maintain efficacy against Omicron, but antibody drugs are substantially less effective.

Estudo randomizado | Suplementação de vitamina D para idosos (média de idade: 67 anos) por 5 anos reduziu o risco de doenças autoimunes em 22%. O risco absoluto no grupo em tratamento foi de 0,95% vs. 1,19% no grupo placebo.

31 Jan, 2022 | 08:51h

Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial – The BMJ

Comentário: Vitamin D and fish oil supplements may help prevent autoimmune disease, study says – CNN

Conteúdos relacionados:

RCT: Oral Vitamin D supplementation (60.000 IU per month) did not reduce mortality in patients 60 years or older (unscreened individuals in Australia, many without insufficiency, average 30ng/mL). Exploratory analyses pointed towards an increased risk of death from cancer.

RCT: Vitamin D supplementation is not beneficial for the prevention of cardiovascular disease and cancer.

USPSTF Draft Statement: Insufficient evidence to recommend multivitamin supplements for the prevention of CVD or cancer. The statement also recommends against the use of beta-carotene (increases risk of CVD mortality and lung cancer) or vitamin E (clear evidence of no benefit)

USPSTF Statement: Insufficient evidence to recommend Vitamin D deficiency screening

Vitamin D, calcium, other vitamins, and supplements do not prevent cardiovascular diseases

Resumo de diretriz | Tratamento dos 10 eventos adversos imunológicos mais comuns em pacientes em imunoterapia.

31 Jan, 2022 | 08:39h

Management of the Top 10 Most Common Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy – JCO Oncology Practice

Artigo original: ASCO Guideline Update: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy.

Conteúdos relacionados:

Clinical practice guideline on immune checkpoint inhibitor-related adverse events.

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities (várias fontes sobre o tema)

Estudo randomizado | Imunoglobulina hiperimune não melhorou os desfechos de pacientes internados com COVID-19.

28 Jan, 2022 | 17:24h

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial – The Lancet

Comentários:

High-dose immunoglobulins from convalescent donors for patients hospitalised with COVID-19 – The Lancet

Hyperimmune intravenous immunoglobulin does not improve outcomes for adults hospitalized with COVID-19 – NIH News Releases

Perspectiva | A variante Ômicron tornará imune a maioria de nós?

28 Jan, 2022 | 17:18h

Will Omicron Leave Most of Us Immune? – The Atlantic